Future analyses in EGFR mutant NSCLC patients could evaluate whether the expression of STYK1 can be used as a biomarker to predict progression-free survival and prognosis in response to EGFR inhibitors. This evidence concerns the gene STYK1 and non-small cell lung carcinoma.